

May 22nd to 24th 2025

Workshop & Symposium „Tumor Immunology meets Oncology XIX“

Medical School “Theodor Fontane” Brandenburg
Institute of Translational Immunology
Martin Luther University Halle-Wittenberg
Medical Faculty
Prof. Dr. Barbara Seliger



WELCOME TO Brandenburg
Altstädtisches Rathaus 10

Dear colleagues and friends,

it is a great pleasure for us to welcome you for the second time in Brandenburg an der Havel for our meeting „Tumor immunology meets oncology (TIMO XIX)“. We expect 2025 again an exceptional participation of international and national colleagues due to the growing interest in immunotherapies.

The topics of the meeting are next to different immune escape mechanisms, the role of the tumor microenvironment and microbiome in tumor progression and therapy response and the use of biomarkers as critical determinants for therapy response and resistance. These will be complemented by reports on machine learning approaches and novel therapeutic strategies including combination treatments in order to revert the immune escape and enhance tumor immunogenicity to optimize and improve the efficacy of these immunotherapies.

The aim of this meeting is to link basic and translational research with clinical implementation. Despite the success of immunotherapies for the treatment of many tumor entities, only a limited number of patients does respond. Thus, novel strategies to enhance therapy response and the patients' outcome are urgently needed by e.g., reprogramming of immune inhibitory properties of the tumor and its immune suppressive environment.

TIMO XIX brings together an extraordinary group of international and national scientists and clinicians focused on tumor immunology and immunotherapy, but it also serves as platform for young researchers in this field to present their own work and discuss novel aspects of anti-tumor immune responses and of treatment of different cancers with distinct immunotherapeutic approaches. The meeting will promote the scientific exchange and will foster collaborations.

We would like to thank you for coming to Brandenburg an der Havel and we hope that you leave the conference with novel insights for your own basic and translational research, but also with impressions of the beauty and hospitality of the city.

We express our gratitude to all who were involved in the organization as well as to the sponsors of this event.

General information

The TIMO registration desk is located in the lobby of the Old Town Hall. Faculties and/ or companies are required to upload their presentation not later than half an hour before the session starts.

Poster session will take place at 22nd of May from 06.00 to 07.30 p.m. It offers an opportunity for continued network and provides education in a relaxed atmosphere, where attendees can interact with poster presenters one by one. The three best talks in the workshop and posters will be selected by a jury and awarded prizes.



Workshop program „Tumor immunology“

Date: 22nd of May 2025

Venue: Old Town Hall

Research Area:

Inflammation & Tumorigenesis

9.00 a.m. **Introduction** (Barbara Seliger)

Chair: Julia Schröder (Brandenburg, GER)

09.10 – 09.35 a.m.

Mechanisms of chronic inflammation, aging and protein accumulation in skeletal muscle

Jens Schmidt (Brandenburg, GER)

09.35 – 09.55 a.m.

Biglycan and inflammation

Christoforos Vaxevanis (Halle, GER)

09.55 – 10.20 a.m.

Butyrate and guanylate cyclase-C agonists have synergistic anti-inflammatory and tumor suppressive effects in experimental colonic tumorigenesis

Sören Ocvirk (Potsdam, GER)

10.20 – 10.45 a.m.

Contextualizing cancer immunity in space: Does it truly matter?

Noël de Miranda (Leiden, NL)

10.45 – 11.10 a.m.

Impact of dose and fractionation of radiotherapy on local vs. distant cancer control

Aitziber Buqué Martinez (Philadelphia, USA)

11.15 – 12.15 a.m. Snacks and scientific exchange

12.15 – 12.30 p.m.

Introduction Workshop (Barbara Seliger)

Chair: Claudia Arndt (Dresden, GER)

Bladimiro Rincón Orozco (Santander, COL)

12.30 – 12.45 p.m.

Impaired dendritic cell differentiation in multiple myeloma

Stella Autenrieth (Heidelberg, GER)

12.45 – 01.00 p.m.

Unconventional functions of immune-related microRNAs

Yuan Wang (Halle, GER)

01.00 – 01.15 p.m.

Functional consequences of the genomic deletion of PD-1 and TIGIT on melanoma-specific T lymphocytes

James Goward (Nantes, FRA)

01.15 – 01.30 p.m.

Targeting LEDGF/p75 in 3D tumor spheroids: a CRISPR/Cas9 approach to understand cancer progression and drug resistance

Victoria Liedtke (Cottbus-Senftenberg, GER)

01.30 – 01.45 p.m.

Fibroblast activation protein link on modulating extracellular matrix and immune escape in anaplastic thyroid carcinoma

Mario Udinotti (Halle, GER)

01.45 – 02.00 p.m.

Involvement of the NLRC5 / MHC class I axis in human colorectal cancer immune surveillance

Mathilde Deiber (Nantes, FRA)

02.00 – 02.15 p.m.

Oxidized melanoma antigens promote activation and proliferation of cytotoxic T cell subpopulations

Sander Bekeschus (Rostock, GER)

02.15 – 02.30 p.m.

Regulatory role of miR-128-3p in CREB1 and its impact on HER2/neu-positive breast cancer

Dimitris Kokoretsis (Halle, GER)

02.30 – 02.45 p.m.

Identification of immune evasion mechanisms in colorectal cancer

Lennart Heere (Berlin, GER)

02.45 – 03.15 p.m. – Coffee break

Chair: Janine Kah (Brandenburg, GER)

Michael Bachmann (Dresden, GER)

03.15 – 03.30 p.m.

Analyses of the effects of radiotherapy and cannabidiol (CBD) on the immune phenotype of breast cancer cells

Yunyun Tang (Erlangen, GER)

03.30 – 03.45 p.m.

Targeting T cells and macrophages in patient-derived tissue cultures with bispecific antibodies against CEACAM5

Sonja Kallendrusch (Potsdam, GER)

03.45 – 04.00 p.m.

Enhanced tissue residency immunoprofile and effector functions in tumor-infiltrating lymphocytes expanded from tumors following chemotherapy

Jessica Kamicki (Lisboa, PRT)

04.00 – 04.15 p.m.

Immortalized NK92 cells exhibit a consistent cytotoxic effect on viral hepatitis-induced hepatocellular carcinoma cell lines

Svenja Stefanski (Brandenburg, GER)

04.15 – 04.30 p.m.

Anti-CD19 IL12 CAR T cells for the eradication of antigen loss leukemia cells

Celine Dreger (Regensburg, GER)

04.30 – 04.45 p.m.

Novel FAPI target modules for diagnostic imaging, endoradiotherapy and UniCAR T cell immunotherapy

Hugo Boutier (Dresden, GER)

04.45 – 05.00 p.m.

Stromal cells modulate innate immune cell phenotype and function in colorectal cancer via the Sialic acid/ Siglec axis

Aideen Ryan (Galway, IRE)

05.00 – 05.15 p.m.

Mitochondrial metabolic reprogramming of human T cells: Changes in their immunophenotype and enhancement of cytotoxic capacity have the potential to boost adoptive immunocellular therapies against cervical cancer

Bladimiro Rincón Orozco (Santander, COL)

05.15 – 05.30 p.m.

Ultrahigh-plex and high-throughput spatial biology solutions: From discovery to the clinic

Stefan Scory (Köln, GER)

05.30 – 05.45 p.m.

The role of radiomics and comprehensive volumetric assessment in early-phase oncological drug development

Andrea Corsi (Liège, BEL)

05.45 – 06.00 p.m.

The versatility of VSV-GP as a platform for oncolytic viruses and cancer vaccines

Abhilash Chiramel (Ochsenhausen, GER)

Poster session „Tumor immunology“

Date: 22nd of May 2025, 06.00 – 07.30 p.m.

Venue: Old Town Hall

Chair: Douglas McNeel (Madison, USA)

Markus Maeurer (Lisboa, PRT)

1. Development of a new therapeutic vaccination strategy based on long artificial synthetic peptides in melanoma

Amélie Guiho (Nantes, FR)

2. Development of a novel, switchable adapter chimeric antigen receptor (CAR) T cell platform against prostate cancer antigen PSMA

Rutuja Gupte (Dresden, GER)

3. EGFL7, an angiogenic protein, acts as an immunosuppressive factor in glioma development

Sukrit Mahajan (Dresden, GER)

4. Recovery of NK92 cell cytotoxicity after expansion

Gregor Mattert (Brandenburg, GER)

5. Microbially produced deoxycholic acid drives colonic tumorigenesis and alters abundances of immune cell populations in the gut of gnotobiotic mice cancer

Annika Oßwald (Rehbrücke, GER)

6. Targeting Langerhans cells via mannosylated nucleic acid-based scaffolds for cancer vaccination

Antonia Resag (Dresden, GER)

7. Understanding PRELP and its interactions: Implications for melanoma treatment strategies

Karthikeyan Subbarayan (Halle, GER)

8. Biglycan as a mediator of bone marrow fibrosis in myeloid malignancies

Christoforos Vaxevanis (Halle, GER)

9. FLASHlab@PITZ: Prooxidant and apoptotic effects of ultra-high dose rate electron irradiation in vitro

Sepideh Aminzadeh-Gohari (Zeuthen, GER)

10. Oxidation using medical gas plasma induces cellular toxicity with immunogenic characteristics in primary cultures of high-grade glioma cells

Finn Christopher Robert (Vienna, AUT)

11. Type I conventional dendritic cells and CD8+ T cells predict favorable clinical outcome of head and neck squamous cell carcinoma patients

Rebecca Rothe (Dresden, GER)

12. PD-1 inhibition in patient-derived tumor cultures (PDTs) characterizes tumor viability and immunological adaptation

Ngoc Anh Hoang (Potsdam, GER)

13. Spheres in tumor-Infiltrating lymphocyte (TIL) expansions: complex structures containing T and B cells resembling tertiary lymphoid structures (TLS)

Rodrigo Manuel Eduardo (Lisboa, POR)

14. Investigating the role of DANCER and IFI6 in PRELP-mediated immune regulation in melanoma

SM Al Amin Hossain (Halle, GER)

15. VXM01, a novel anti-VEGFR-2 oral vaccine in combination with avelumab-mediated PD-L1 inhibition is well-tolerated in an open-label Phase 2a clinical trial in patients with recurrent glioblastoma

Constance Höfer (Mannheim, GER)

16. Tamoxifen adapted breast cancer cell lines exhibit changes in gene expression of the MHC class II antigen presentation pathway

Norbert Naß (Brandenburg, GER)

17. Analysis of prognostic and immunological markers in non-small cell lung carcinoma during radiation therapy – an explorative analysis with focus on potential biomarkers

Lisa Witte (Halle, GER)

18. Myopalladin may be involved in mediating acquired resistance to EGFR inhibitors in head and neck squamous cell carcinoma

Jianbo Zhao (Halle, GER)

SYMPOSIUM PROGRAM

Symposium program „Tumor immunology“

Date: 23rd of May 2025

Venue: Old Town Hall

08.30 a.m. **Welcome and introduction**

Steffen Scheller (Mayor of the City Brandenburg)

Christine Holmberg (Dean of the MHB) & Barbara Seliger (Brandenburg/Halle)

Session: Immune escape

Chair: Stina Wickström/ Ravid Straussman

8.45 – 09.15 a.m.

Barbara Seliger (Brandenburg/Halle, GER)

Interplay of intrinsic and extrinsic immune escape mechanisms of tumors

09.15 – 09.45 a.m.

Robert Zeiser (Freiburg, GER)

Immune escape in acute leukemia

09.45 – 10.15 a.m.

Luis Zapata-Ortiz (London, GBR)

Convergent evolution of immune escape and inflammatory mechanisms as a late marker of tumorigenesis

10.15 – 10.45 a.m.

Markus Maeurer (Lisboa, PRT)

Rewire and un-learn are key elements for successful anti-tumor directed immune responses

10.45 – 11.15 a.m. Coffee break

Session: NK cells

Chair: Sumit K. Subudhi/ Robert Zeiser

11.15 – 11.45 a.m.

Lorenzo Moretta (Rome, ITA)

Human NK cells, from surface receptors to the therapy of high risk leukemias – a historical overview

11.45 – 12.15 p.m.

Adelheid Cerwenka (Heidelberg, GER)

Checkpoints of NK cell reactivity in the tumor microenvironment

12.15 – 12.45 p.m.

Per Thor Straten (Herlev, DK)

The exercise of mobilizing the immune system in cancer patients

12.45 – 01.45 p.m. Lunch break and poster viewing

Key note lecture

01.45 – 01.50 p.m.

Introduction: Barbara Seliger (Brandenburg/Halle, GER)

01.50 – 02.15 p.m.

Sergio Quezada (London, GBR)

Targeting regulatory T cells in cancer: Mechanisms, challenges and novel therapies

Session: Immune metabolism and microbiome

Chair: Chiara Massa/ Luis Zapata-Ortiz

02.15 – 02.45 p.m.

Shuji Ogino (Boston, USA)

Integrative science of (micro-)environment, microbiota, immunity and tumors (e.g. early-onset cancer)

02.45 – 03.15 p.m.

Ravid Straussman (Rehovot, ISR)

The tumor microbiome and its effects on the response to immunotherapy

03.15 – 03.45 p.m.

Lorenzo Galluzzi (Philadelphia, USA)

Mitochondria at the hub of cell death and immunity in irradiated cancer cells

03.45 – 04.15 p.m. Coffee break

Session: Biomarkers and bioinformatics

Chair: Per Thor Straten/ Christine Dierks

04.15 – 04.45 p.m.

Hubert Hackl (Innsbruck, AUT)

Determinants of combination immunotherapies

04.45 – 05.15 p.m.

Simon Knott (Los Angeles, USA)

Spatial transcriptomic features predictive of neoadjuvant response in triple negative breast cancer

05.15 – 05.45 p.m.

Sumit K. Subudhi (Houston, USA)

Strategies to overcome the immunosuppressive prostate tumor microenvironment

05.45 – 06.15 p.m.

Kristoffer Haurum Johansen (Lyngby, DK)

AI-generated de-novo pMHC minibinders can direct T cells for cancer cell killing

Friday, 23rd of May 2025

08.00 p.m. DINNER for all

Networking event

Theaterklause Brandenburg



Symposium program „Tumor immunology”

Date: 24th of May 2025

Venue: Old Town Hall

Session: Immunotherapy approaches

Chair: Marion Subklewe/ Simon Knott

08.00 – 08.30 a.m.

Michael Bachmann (Dresden, GER)

Theranostic tumor targeting

08.30 – 09.00 a.m.

Michele Maio (Siena, ITA)

Epigenetic approaches in melanoma

09.00 – 09.30 a.m.

Ofer Mandelboim (Jerusalem, ISR)

Development of specific treatment for fusobacterium nucleatum bearing tumors

09.30 – 10.00 a.m.

Douglas G. McNeel (Madison, USA)

Clinical trial of androgen deprivation, anti-tumor vaccine and nivolumab in patients with newly diagnosed, high-risk prostate cancer

10.00 – 10.30 a.m. Coffee break

Session: Innovative cell therapies

Chair: Adelheid Cerwenka/ Shuji Ogino

10.30 – 11.00 a.m.

Christine Dierks (Halle, GER)

Kinase inhibitors enhance CART cell efficiency in solid tumors

11.00 – 11.30 a.m.

Marion Subklewe (Munich, GER)

Unleashing T cells against AML: CARs, BiTEs and emerging Strategies

11.30 – 12.00 a.m.

Stina Wickström (Stockholm, SWE)

Adoptive TIL therapy: a role for DC vaccine, neoantigens and the immunoproteasome

12.00 – 12.30 p.m.

Bernard Fox (Portland, USA)

Dark matter of cancer: non-conventional peptides as novel therapeutic targets

12.30 – 12.45 p.m.

Jörg Wischhusen (Würzburg, GER)

Wrap up and closing remarks



REGISTRATION FEE:

Payable until 30th of April 2025

industry without sponsoring: 500 €

participants: 300 €

MHB members and PhD students: 200 €

Bachelor/ Master/ MD students from the MHB: free

Bank name:

Sparkasse Ostprignitz-Ruppin

IBAN: DE03 1605 0202 1001 0224 55

SWIFT code: WELADED1OPR

Purpose of use: Kst. 19230525, name, TIMO XIX

SYMPOSIUM SECRETARY:

Sandra Wolf

Institute for Translational Immunology

Brandenburg Medical School (MHB)

Gertrud-Piter-Platz 7

14770 Brandenburg an der Havel

Tel. +49 3381 2182216

e-mail: sandra.wolf@mhb-fontane.de

The Medical Association of Brandenburg credits this educational activity with 3 points (workshop) and 12 points (symposium).

WE THANK OUR SPONSORS:

Akoya Biosciences, Becton Dickinson, DFG, Generic Assays GmbH, Sarstedt, SITC, 10 x GENOMICS

Special thanks to the **Old Town Hall Brandenburg**

We thank Michael Hoetzel, DGPh for the Copyright of the photos.

Email: info@michaelhoetzel.de



in cooperation with



Society for Immunotherapy of Cancer



**Institute of Translational Immunology
& Medical Faculty**

**Prof. Dr. Barbara Seliger
Director of FOCIS Center of Excellence**

**Medical School Brandenburg
Martin Luther University Halle-Wittenberg**

**Tel. +49 3381 2182216
+49 345 5574054**

barbara.seliger@uk-halle.de